$BMRAMay 28, 2026, 8:19 AM ETAI processed
BMRA signs $1.75M+ CDMO master services agreement to develop IVD assays
AI Summary
Biomerica (BMRA) signed a three-year CDMO Master Services Agreement with a confidential life sciences company to develop proprietary in vitro diagnostic assays, with an initial contract development target fee of over $1.75 million to be earned across multiple Statements of Work. All development will be performed at Biomerica's FDA‐licensed, ISO 13485 facility and revenue will be recognized on milestone acceptance; the engagement uses existing staff and equipment, providing near-term revenue visibility while the company continues to prioritize commercialization of its inFoods IBS diagnostic.
Positives
- Initial development target fee > $1.75M provides near-term revenue visibility
- Three-year MSA with automatic one-year renewals establishes a multi-year engagement framework
- Work to be completed at FDA-licensed, ISO 13485-certified facility using existing team — capital-light, potential operating leverage
Negatives
- Partner identity is confidential, limiting transparency on counterparty strength
- The $1.75M estimate is spread across multiple SOWs and no revenue is recognized until SOWs are executed and milestones accepted
- MSA revenue is contingent on SOW execution and subject to cancellation or termination risk